Literature DB >> 10915088

Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.

P Kazanjian1, W Armstrong, P A Hossler, W Burman, J Richardson, C H Lee, L Crane, J Katz, S R Meshnick.   

Abstract

This study was conducted to determine whether Pneumocystis carinii dyhydropteroate synthase (DHPS) gene mutations in AIDS patients with P. carinii pneumonia (PCP) are affected by duration of sulfa or sulfone prophylaxis and influence response to sulfa or sulfone therapy. The P. carinii DHPS genes from 97 AIDS patients with PCP between 1991 and 1999 from 4 medical centers were amplified, using polymerase chain reaction (PCR), and sequenced. Mutations were observed in 76% of isolates from patients exposed to sulfa or sulfone prophylaxis compared with 23% of isolates from patients not exposed (P=.001). Duration of prophylaxis increased the risk of mutations (relative risk [RR] for each exposure month, 1.06; P=.02). Twenty-eight percent of patients with mutations failed sulfa or sulfone treatment; mutations increased the risk of sulfa or sulfone treatment failure (RR, 2.1; P=0.01). Thus, an increased duration of sulfa or sulfone prophylaxis increases the chance of developing a P. carinii mutation. The majority of patients with mutations respond to sulfa or sulfone therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915088     DOI: 10.1086/315719

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Genetic analysis of multiple loci suggests that mutations in the Pneumocystis carinii f. sp. hominis dihydropteroate synthase gene arose independently in multiple strains.

Authors:  L Ma; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Genotypes of Pneumocystis jiroveci isolates obtained in Harare, Zimbabwe, and London, United Kingdom.

Authors:  Robert F Miller; Austin R Lindley; Helen E Ambrose; Adam S Malin; Ann E Wakefield
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

3.  Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation.

Authors:  C Annaloro; A Della Volpe; P Usardi; G Lambertenghi Deliliers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

4.  High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa.

Authors:  Leigh Dini; Mignon du Plessis; John Frean; Victor Fernandez
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

Review 5.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

Review 6.  Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.

Authors:  Aleksey Porollo; Jaroslaw Meller; Yogesh Joshi; Vikash Jaiswal; A George Smulian; Melanie T Cushion
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465

Review 7.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.

Authors:  P D Walzer; A Ashbaugh; M Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort.

Authors:  Christina Yoon; Anuradha Subramanian; Amy Chi; Kristina Crothers; Steven R Meshnick; Steve M Taylor; Charles B Beard; Leah G Jarlsberg; Gena G Lawrence; Melissa Avery; Alexandra Swartzman; Serena Fong; Brenna Roth; Laurence Huang
Journal:  Med Mycol       Date:  2013-03-08       Impact factor: 4.076

10.  Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia.

Authors:  Aimable Nahimana; Meja Rabodonirina; Jannik Helweg-Larsen; Isabelle Meneau; Patrick Francioli; Jacques Bille; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.